2 terminated, 1 active not recruiting, 1 recruiting. 4 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Terminated 2, Active not recruiting 1, Recruiting 1 |
| Phase 2 | 2 | Active not recruiting 1, Recruiting 1 |
Follow Recurrent Myeloproliferative Neoplasm: new trials by email Literature Review of Recurrent Myeloproliferative Neoplasm trials Research Report on Recurrent Myeloproliferative Neoplasm
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia Axatilimab, Azacitidine, Biospecimen Collection - Atypical Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia | Phase 1 / Phase 2 | Recruiting | Uma Borate | 49 | 2024-08-02 | 2026-08-27 |
| Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia Cytarabine, Filgrastim, Fludarabine - Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome | Phase 1 | Terminated | Northwestern University | 2 | 2020-12-21 | 2026-06-01 |
| Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations Azacitidine, Quizartinib - Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 30 | 2020-07-21 | 2026-10-05 |
| Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial Abemaciclib, Abiraterone, Afatinib - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Terminated | OHSU Knight Cancer Institute | 2 | 2020-04-01 | 2024-03-04 |
Myeloproliferative Disorders (4) · Leukemia, Myelomonocytic, Chronic (3) · Myelodysplastic Syndromes (3) · Leukemia, Myeloid, Acute (2) · Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative (2) · Myelodysplastic-Myeloproliferative Diseases (2) · Anemia (1) · Blast Crisis (1) · Breast Neoplasms (1) · Hematologic Neoplasms (1) · Hodgkin Disease (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Leukemia, Myeloid, Accelerated Phase (1) · Leukemia, Myeloid, Chronic-Phase (1)
Bone Marrow Diseases (4) · Hematologic Diseases (4) · Hemic and Lymphatic Diseases (4) · Leukemia (4) · Leukemia, Myeloid (4) · Neoplasms (4) · Neoplasms by Histologic Type (4) · Chronic Disease (3) · Disease Attributes (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Blood Platelet Disorders (1) · Blood Protein Disorders (1) · Breast Diseases (1) · Carcinogenesis (1)
Azacitidine (2) · Specimen Handling (2) · 130-nm albumin-bound paclitaxel (1) · 2C4 antibody (1) · Ado-Trastuzumab Emtansine (1) · Afatinib (1) · Albumin-Bound Paclitaxel (1) · Bevacizumab (1) · Biopsy (1) · Bortezomib (1) · CTLA-4 Antigen (1) · Capecitabine (1) · Carboplatin (1) · Celecoxib (1) · Cytarabine (1)
M.D. Anderson Cancer Center (1) · Northwestern University (1) · OHSU Knight Cancer Institute (1) · Uma Borate (1)
United States (4)
Guillermo M Bravo (1) · Lara Davis, MD (1) · Shira N Dinner, M.D. (1) · Uma M Borate, MD (1)
P30CA060553 (1)